Company intelligence / Profile preview

CuraX

Brentwood, Tennessee, United States

Ownership: Private
Development stage: Other

Overview

Currax Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on chronic, progressive diseases, currently marketing several small-molecule products (including naltrexone + bupropion for obesity, sumatriptan nasal powder and sumatriptan + naproxen for migraine, and doxepin for sleep) and developing additional once-daily and combination obesity therapies, an obesity maintenance therapy, and a therapy focused on weight gain in use disorder, with at least one large cardiovascular outcomes trial ongoing for its obesity product portfolio.[3][4]

Therapeutic areas: EndocrinologyCardiovascularNeurologyMetabolic DisordersPsychiatry
Modalities: Small moleculeDevice
Industry: Biotech

Beyond the preview

Go deeper on CuraX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CuraX.

Explore the full profile